文献速递呼吸道感染呼吸危重症与机械通气

肥胖与呼吸机相关性肺炎的关系:NUTRIREA2试验的事后分析

Relationship Between Obesity and Ventilator-Associated Pneumonia: A Post Hoc Analysis of the NUTRIREA2 Trial.
PubMed 文献 · Chest · 2021-02-06

本研究为NUTRIREA2随机对照试验的事后分析,纳入2325例接受有创机械通气和血管升压药支持的成人患者,其中699例(30%)为肥胖(BMI≥30 kg/m2)。

要点

  • 肥胖与机械通气时长和ICU住院时间无显著差异。

核心结论

  • 肥胖对呼吸机相关性肺炎的发生率无显著影响。

研究设计与样本

  • NUTRIREA2开放标签随机对照试验的事后分析,在44个法国ICU进行,纳入2325例接受有创机械通气和血管升压药支持的成人患者。
  • 肥胖定义为ICU入院时BMI≥30 kg/m2,共699例(30%)患者为肥胖。
  • VAP诊断由独立盲法委员会根据临床、影像和微生物学数据裁定,仅纳入首次VAP发作。

主要发现

  • 共诊断224例首次VAP,肥胖组60例,非肥胖组164例。
  • 在123例子组中,胃内容物或口咽分泌物大量微吸入率在肥胖与非肥胖患者间无显著差异。

关键数值与推荐

  • 肥胖定义:ICU入院时BMI≥30 kg/m2。
  • VAP发生率分析采用Fine and Gray模型,以拔管和死亡为竞争风险。

临床怎么用

  • 对于肥胖的机械通气患者,不应仅因肥胖而额外增加VAP预防措施。
  • 肥胖患者机械通气期间VAP风险未升高,但需关注其他并发症。
  • 肥胖与较低90天死亡率相关,需进一步研究其机制。

局限性

  • 本研究为事后分析,可能存在残余混杂。
  • VAP诊断依赖独立委员会裁定,但部分患者缺乏微吸入生物标志物数据。
  • 研究人群为接受血管升压药支持的休克患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with obesity are at higher risk for community-acquired and nosocomial infections. However, no study has specifically evaluated the relationship between obesity and ventilator-associated pneumonia (VAP). RESEARCH QUESTION: Is obesity associated with an increased incidence of VAP? STUDY DESIGN AND METHODS: This study was a post hoc analysis of the Impact of Early Enteral vs Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines (NUTRIREA2) open-label, randomized controlled trial performed in 44 French ICUs. Adults receiving invasive mechanical ventilation and vasopressor support for shock and parenteral nutrition or enteral nutrition were included. Obesity was defined as BMI ≥ 30 kg/m2 at ICU admission. VAP diagnosis was adjudicated by an independent blinded committee, based on all available clinical, radiologic, and microbiologic data. Only first VAP episodes were taken into account. Incidence of VAP was analyzed by using the Fine and Gray model, with extubation and death as competing risks. RESULTS: A total of 699 (30%) of the 2,325 included patients had obesity; 224 first VAP episodes were diagnosed (60 and 164 in obese and nonobese groups, respectively). The incidence of VAP at day 28 was 8.6% vs 10.1% in the two groups (hazard ratio, 0.85; 95% CI 0.63-1.14; P = .26). After adjustment on sex, McCabe score, age, antiulcer treatment, and Sequential Organ Failure Assessment at randomization, the incidence of VAP remained nonsignificant between obese and nonobese patients (hazard ratio, 0.893; 95% CI, 0.66-1.2; P = .46). Although no significant difference was found in duration of mechanical ventilation and ICU length of stay, 90-day mortality was significantly lower in obese than in nonobese patients (272 of 692 [39.3%] patients vs 718 of 1,605 [44.7%]; P = .02). In a subgroup of patients (n = 123) with available pepsin and alpha-amylase measurements, no significant difference was found in rate of abundant microaspiration of gastric contents, or oropharyngeal secretions between obese and nonobese patients. INTERPRETATION: Our results suggest that obesity has no significant impact on the incidence of VAP.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Nseir S, Le Gouge A, Pouly O, et al. Relationship Between Obesity and Ventilator-Associated Pneumonia: A Post Hoc Analysis of the NUTRIREA2 Trial. Chest. 2021. PMID: 33561455. doi:10.1016/j.chest.2021.01.081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。